RS62665B1 - Kristalni oblik magl inhibitora - Google Patents

Kristalni oblik magl inhibitora

Info

Publication number
RS62665B1
RS62665B1 RS20211501A RSP20211501A RS62665B1 RS 62665 B1 RS62665 B1 RS 62665B1 RS 20211501 A RS20211501 A RS 20211501A RS P20211501 A RSP20211501 A RS P20211501A RS 62665 B1 RS62665 B1 RS 62665B1
Authority
RS
Serbia
Prior art keywords
crystalline form
magl inhibitor
magl
inhibitor
crystalline
Prior art date
Application number
RS20211501A
Other languages
English (en)
Inventor
Cheryl A Grice
Todd K Jones
Kurt G Grimm
Jacqueline Lorayne Blankman
Channing Rodney Beals
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of RS62665B1 publication Critical patent/RS62665B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20211501A 2016-11-16 2017-11-15 Kristalni oblik magl inhibitora RS62665B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423126P 2016-11-16 2016-11-16
PCT/US2017/061875 WO2018093953A1 (en) 2016-11-16 2017-11-15 Crystalline forms of a magl inhibitor
EP17872429.0A EP3541807B1 (en) 2016-11-16 2017-11-15 A crystalline form of a magl inhibitor

Publications (1)

Publication Number Publication Date
RS62665B1 true RS62665B1 (sr) 2021-12-31

Family

ID=62145805

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20211501A RS62665B1 (sr) 2016-11-16 2017-11-15 Kristalni oblik magl inhibitora
RS20231263A RS65016B1 (sr) 2016-11-16 2017-11-15 Kristalni oblik magl inhibitora

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20231263A RS65016B1 (sr) 2016-11-16 2017-11-15 Kristalni oblik magl inhibitora

Country Status (36)

Country Link
US (2) US11142517B2 (sr)
EP (2) EP3964503B1 (sr)
JP (2) JP7042548B2 (sr)
KR (1) KR102508739B1 (sr)
CN (2) CN110291083B (sr)
AU (1) AU2017361257B2 (sr)
BR (1) BR112019010003A2 (sr)
CA (1) CA3043610A1 (sr)
CL (1) CL2019001340A1 (sr)
CO (1) CO2019005045A2 (sr)
CR (1) CR20190242A (sr)
CY (1) CY1124870T1 (sr)
DK (1) DK3541807T3 (sr)
DO (1) DOP2019000120A (sr)
EA (1) EA201991086A1 (sr)
EC (1) ECSP19035171A (sr)
ES (2) ES2900016T3 (sr)
GE (1) GEP20237559B (sr)
HR (2) HRP20231697T1 (sr)
HU (2) HUE056973T2 (sr)
IL (1) IL266548A (sr)
JO (1) JOP20190109B1 (sr)
LT (1) LT3541807T (sr)
MA (2) MA46866B1 (sr)
MX (2) MX2019005767A (sr)
NI (1) NI201900053A (sr)
PE (1) PE20191239A1 (sr)
PH (1) PH12019501068A1 (sr)
PL (2) PL3964503T3 (sr)
PT (1) PT3541807T (sr)
RS (2) RS62665B1 (sr)
SI (1) SI3541807T1 (sr)
TN (1) TN2019000151A1 (sr)
UA (1) UA124585C2 (sr)
WO (1) WO2018093953A1 (sr)
ZA (1) ZA201903093B (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101653473B1 (ko) 2012-01-06 2016-09-01 어바이드 테라퓨틱스, 인크. 카르바메이트 화합물 및 그의 제조 및 이용 방법
MX2017014344A (es) 2015-05-11 2018-04-11 Abide Therapeutics Inc Metodos para el tratamiento de la inflacion o el dolor neuropatico.
WO2018053447A1 (en) 2016-09-19 2018-03-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MX2019005769A (es) 2016-11-16 2019-12-05 Lundbeck La Jolla Research Center Inc Formulaciones farmaceuticas.
PE20191239A1 (es) 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
EA201992409A1 (ru) 2017-05-23 2020-03-23 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Ингибиторы magl на основе пиразола
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
US11332453B2 (en) * 2018-05-15 2022-05-17 H. Lundbeck A/S MAGL inhibitors
MX2021000549A (es) * 2018-07-19 2021-03-25 Pfizer Compuestos espiro heterociclicos como inhibidores de magl.
AU2020383502A1 (en) * 2019-11-15 2022-06-30 H. Lundbeck A/S Crystalline forms of a MAGL inhibitor
EP4139288A1 (en) * 2020-04-21 2023-03-01 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
DK0580860T4 (da) 1991-04-16 2005-03-21 Nippon Shinyaku Co Ltd Fremgangsmåde til fremstilling af en fast dispersion
KR100274734B1 (ko) 1991-11-22 2000-12-15 제이코버스 코넬리스 레이서 리제드로네이트 지연-방출성 조성물
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EP0827402A2 (en) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1365761A1 (en) 2000-12-18 2003-12-03 Novartis AG Therapeutic combination of amlodipine and benazepril
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
ES2319886T3 (es) 2002-02-20 2009-05-14 Abbott Laboratories Compuestos azabiciclicos condensados que inhiben el sutipo 1 del receptor valinoide (vr1).
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
MX2008006888A (es) 2005-11-28 2008-09-30 Marinus Pharmaceuticals Formulas y metodos para la manufactura y uso de la ganaxolona.
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
FR2938341A1 (fr) 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CN101530399B (zh) 2009-04-15 2011-01-26 江苏中兴药业有限公司 一种水飞蓟宾固体自乳化片
KR101653473B1 (ko) * 2012-01-06 2016-09-01 어바이드 테라퓨틱스, 인크. 카르바메이트 화합물 및 그의 제조 및 이용 방법
CN104379578B (zh) 2012-03-19 2017-06-09 阿比德治疗公司 氨基甲酸酯化合物及其制备和使用方法
EP2844247A4 (en) 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
LT2914248T (lt) 2012-11-02 2018-11-26 Vertex Pharmaceuticals Incorporated Farmacinės kompozicijos, skirtos cftr medijuotų ligų gydymui
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2015003002A1 (en) 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN103893258B (zh) 2013-12-05 2017-09-29 人福医药集团股份公司 含有广金钱草总黄酮的口服固体制剂及其应用
WO2015164160A1 (en) * 2014-04-21 2015-10-29 Merck Sharp & Dohme Corp. Pharmaceutical salts of an orexin receptor antagonist
WO2015179559A2 (en) * 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US9771341B2 (en) 2015-03-18 2017-09-26 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
MX2017014344A (es) 2015-05-11 2018-04-11 Abide Therapeutics Inc Metodos para el tratamiento de la inflacion o el dolor neuropatico.
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
PE20191239A1 (es) 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
MX2019005769A (es) 2016-11-16 2019-12-05 Lundbeck La Jolla Research Center Inc Formulaciones farmaceuticas.
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Also Published As

Publication number Publication date
AU2017361257A1 (en) 2019-05-30
MA46866B1 (fr) 2021-11-30
CN115093382A (zh) 2022-09-23
RS65016B1 (sr) 2024-01-31
JOP20190109B1 (ar) 2022-09-15
CR20190242A (es) 2019-07-09
ES2900016T3 (es) 2022-03-15
EP3964503C0 (en) 2023-11-08
EP3964503B1 (en) 2023-11-08
JP2019537596A (ja) 2019-12-26
CL2019001340A1 (es) 2019-10-04
US20200190063A1 (en) 2020-06-18
TN2019000151A1 (en) 2020-10-05
UA124585C2 (uk) 2021-10-13
MA46866A (fr) 2021-06-02
HUE056973T2 (hu) 2022-04-28
WO2018093953A1 (en) 2018-05-24
US20220235037A1 (en) 2022-07-28
DOP2019000120A (es) 2019-09-30
MX2019005767A (es) 2019-12-05
PT3541807T (pt) 2021-12-09
RU2019116689A (ru) 2020-12-17
EP3541807B1 (en) 2021-09-29
KR20190077561A (ko) 2019-07-03
DK3541807T3 (da) 2021-12-06
PE20191239A1 (es) 2019-09-16
ES2966939T3 (es) 2024-04-25
JOP20190109A1 (ar) 2019-05-09
NI201900053A (es) 2019-10-30
ZA201903093B (en) 2020-11-25
EA201991086A1 (ru) 2019-11-29
PH12019501068A1 (en) 2019-08-19
GEP20237559B (en) 2023-10-25
EP3964503A1 (en) 2022-03-09
HRP20231697T1 (hr) 2024-03-15
SI3541807T1 (sl) 2022-01-31
HUE064559T2 (hu) 2024-03-28
NZ753241A (en) 2021-06-25
HRP20211863T1 (hr) 2022-03-04
US11142517B2 (en) 2021-10-12
RU2019116689A3 (sr) 2021-02-26
JP2022084717A (ja) 2022-06-07
EP3541807A4 (en) 2020-04-22
ECSP19035171A (es) 2019-05-31
JP7042548B2 (ja) 2022-03-28
EP3541807A1 (en) 2019-09-25
CN110291083B (zh) 2022-06-17
CO2019005045A2 (es) 2019-05-31
CN110291083A (zh) 2019-09-27
KR102508739B1 (ko) 2023-03-09
AU2017361257B2 (en) 2022-02-10
BR112019010003A2 (pt) 2019-08-20
MA58133B1 (fr) 2024-02-29
US11993588B2 (en) 2024-05-28
IL266548A (en) 2019-07-31
JP7350117B2 (ja) 2023-09-25
PL3541807T3 (pl) 2022-01-17
CA3043610A1 (en) 2018-05-24
CY1124870T1 (el) 2022-11-25
PL3964503T3 (pl) 2024-04-02
MX2022000249A (es) 2022-02-03
LT3541807T (lt) 2021-12-27

Similar Documents

Publication Publication Date Title
ZA201903093B (en) Crystalline forms of a magl inhibitor
ZA201903100B (en) Magl inhibitors
IL285686B (en) Crystals in solid form in the presence of an inhibitor
IL266550A (en) Magl inhibitors
HUE060953T2 (hu) Eljárások PI3K inhibitor elõállítására
ZA201903099B (en) Magl inhibitors
HK1256806A1 (zh) Pim激酶抑制劑的鹽
GB201522771D0 (en) Crystalline form of a phosphate derivative
IL267393A (en) Crystal forms of a Janus kinase inhibitor
HK1246786A1 (zh) 吡咯並吡啶化合物的結晶形式
ZA201607107B (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
HK1243420A1 (zh) 新型蛋白酶體抑制劑的結晶形式
GB201621619D0 (en) Inhibitor compounds